uploads/2018/09/Biolife-revenue-trend-1.png

BioLife Solutions: On a Strong Footing

By

Updated

Company overview

BioLife Solutions (BLFS) develops, manufactures, and commercializes cell and tissue hypothermic storage and cryopreservation freeze media. Its HypoThermosol and CryoStor platforms are used in biobanking, drug discovery, and regenerative medicine markets.

Article continues below advertisement

Top line

BioLife Solutions generated revenues of $5.18 million in the second quarter compared to $2.56 million in the second quarter of 2017. That increase in revenues was due to growth in BioLife’s regenerative medicine products.

For fiscal 2018 and fiscal 2019, BioLife is expected to generate revenues of $19.89 million and $28.36 million, respectively, compared to $11.02 million in fiscal 2017.

BioLife Solutions incurred cost of sales of $1.54 million in the second quarter compared to $956,839 in the second quarter of 2017. For fiscal 2018, BioLife’s gross margins are expected to be 67.75% compared to 61.2% for fiscal 2017.

BioLife’s research and development expenses increased from $318,607 in the second quarter of 2017 to $324,612 in the second quarter of 2018. Its sales and marketing expenses increased from $546,455 in the second quarter of 2017 to $641,168 in the second quarter of 2018. Its general and administrative expenses increased from $1.08 million in the second quarter of 2017 to $1.39 million in the second quarter of 2018.

The surge in revenues helped BioLife post operating income of $1.28 million in the second quarter of 2018 compared to a loss of $341,203 in the second quarter of 2017.

Next, let’s look at BioLife Solutions’ bottom line and valuation metrics.

Advertisement

More From Market Realist